The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]
Lire la suiteThe Therapeutic Potentials of Ayahuasca : Possible Effects against Various Diseases of Civilization Ede Frecska, Petra Bokor and Michael Winkelman Frontiers in Pharmacology, 2016, Vol 7, Article 35, 1-17. doi: 10.3389/fphar.2016.00035 Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are b-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual consumption has become common among the mestizo populations of South America. Ayahuasca use amongst the indigenous people of the Amazon is a form of traditional medicine and cultural psychiatry. During the last two decades, the [...]
Lire la suiteA Psychotherapeutic View on the Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Addiction Anja LOIZAGA-VELDER MAPS Bulletin Special Edition, Spring 2013, 36-40. Ayahuasca is a traditional plant preparation of the Amazon basin with psychoactive properties. In recent decades ayahuasca has gained the attention of researchers in multiple disciplines worldwide due to its acclaimed therapeutic and spiritual qualities. It is an admixture of two plants : the harmaline containing vine Banisteriopsis caapi, and the DMT-containing leafs from the Psychotria viridis bush. It is typically administered by a trained expert in a ritual context. The use of ayahuasca has spread beyond the Amazon [...]
Lire la suiteAyahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Gerald Thomas, Philippe Lucas, N. Rielle Capler, Kenneth W. Tupper and Gina Martin Current Drug Abuse Reviews, 2013, 6, (1), 1-13. Abstract: Introduction : This paper reports results from a preliminary observational study of ayahuasca-assisted treatment for problematic substance use and stress delivered in a rural First Nations community in British Columbia, Canada. Methods : The “Working with Addiction and Stress” retreats combined four days of group counselling with two expert-led ayahuasca ceremonies. This study collected pre-treatment and six months follow-up data from 12 participants on several psychological and behavioral factors related to [...]
Lire la suiteHallucinogens and redemption Marlene Dobkin de Rios, Charles S Grob, John R Baker Journal of Psychoactive Drugs, 2002, 34, 3, 239-248. Abstract : This article examines drug substitution with regard to hallucinogens (ayahuasca, ibogaine, peyote and LSD) set within the concept of redemption. The model examines both religious and secular approaches to the contemporary use of hallucinogens in drug substitution, both by scientists and in religious setting worlwide. The redemptive model posits that the proper use of one psychoactive substance within a spiritual or clinical context helpsto free an individual from the adverse effects of their addiction to another substance and thus restores them [...]
Lire la suitePsychedelic therapy for smoking cessation : Qualitative analysis of participant accounts Tehseen Noorani, Albert Garcia-Romeu, Thomas C. Swift, Roland R. Griffiths and Matthew W. Johnson Journal of Psychopharmacology, 2018, 1 –14 https://doi.org/10.1177/0269881118780 Abstract Background : Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. Aims : The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long-term outcomes to better understand the therapeutic process. Methods : Participants were [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteAyahuasca Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Genís Oña -2013- Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is ayahuasca? 2. Scientific papers about ayahuasca arranged chronologically (1969-2013) - G. R. Dolmatoff (1969). El contexto cultural de un alucinógeno aborigen : Banisteriopsis Caapi - C. Grob et al. (1996). Human Psychopharmacology of Hoasca, a Plant Hallucinogen Used in Ritual Context in Brazil - J. C. Callaway et al. (1999). Pharmacokinetics of Hoasca Alkaloids in Healthy Humans - B. Shanon (2000). Ayahuasca and [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suiteSalvinorin A : Pharmacology, therapeutic potential and structural considerations of a unique non-nitrogenous selective k-opioid receptor agonist, and active component of the sage Salvia divinorum. Adriano Ciaffoni Graduate School of Life Sciences, Utrecht University July 2014, Utrecht, The Netherlands Summary Salvia divinorum is a plant indigenous of Oaxaca, Mexico. Traditionally, the plant is used for healing and divinatory purposes. At present, S. divinorum is also used recreationally by teenagers and young adults around the world. The main active component is salvinorin A, a unique non-nitrogenous kappa-opioid receptor agonist with hallucinogenic properties. Scientific interest is high, due to two facts: 1) salvinorin A was the first [...]
Lire la suite